Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial

Orlistat for the treatment of antipsychotic-induced weight gain: an eight-week multicenter, randomized, placebo-controlled, double-blind trial

Abstract Background Weight gain and metabolic disorders are commonly induced by antipsychotics. Orlistat is a lipase inhibitor used for weight control. The effect of orlistat on weight gain and metabolic disturbances in people (especially women) treated with antipsychotics has not been sufficiently...

Full description

Bibliographic Details
Main Authors: Peng Xie, Tiannan Shao, Yujun Long, Weiwei Xie, Yangjun Liu, Ye Yang, Yuyan Huang, Renrong Wu, Qijian Deng, Hui Tang
Format: Article
Language:English
Published: BMC 2024-07-01
Series:Lipids in Health and Disease
Subjects:
Antipsychotic
Orlistat
Weight gain
Serum lipid
Online Access:https://doi.org/10.1186/s12944-024-02214-w

Internet

https://doi.org/10.1186/s12944-024-02214-w

Similar Items